Brooks Laboratories Limited (BROOKS) Fair Value & Analysis
Healthcare · IN · Market cap ₹2.2B
Fair value as of: Aug 2, 2026
From 23 valuation models · updated 11 days ago
Share price −10.6% over the past month.
A solid business, but screening 43% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹46.54). The favourable scenario is already priced in.
- Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (₹25.06 to ₹46.54) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 2, 2026.
How to read this chart
60‑month range ₹37.11 – ₹194.97 · fair‑value band ₹25.06 – ₹46.54 · the ₹62.48 price screens above the ₹35.80 fair value. Dashed = 300-day average. As of Aug 2, 2026.
Analysis
Brooks Laboratories Limited (BROOKS) currently trades at ₹62.48, while our model-based Fair Value estimate is ₹35.80, implying the stock looks roughly 42.7% overvalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Brooks Laboratories Limited generated revenue of ₹857M at a net margin of 28.7%. Revenue declined 13.3% year over year. It earns a return on equity of 22.3%. Net debt stands at ₹9.7M. Fundamentals as of Aug 2, 2026
Our scenario range runs from ₹25.06 (bear case) to ₹46.54 (bull case); at ₹62.48, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 62% below its 52-week high and 72% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -43%, BROOKS screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: Growth Earnings (₹150.29) versus Economic Profit (₹19.75). Highest evidence: Growth DCF (80).
Notify me when BROOKS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 2, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally.
Full company description
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also provides regulatory compliance, custom branding and packaging, scalable production, and end-to-end support services. The company serves government health programs and public sector institutions, hospitals and medical colleges, defense and railways, corporate healthcare, and NGOs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan Nigeria, Lebanon, Mauritius, Sudan, Madagascar, DR Congo, Mozambique, LATAM, and Africa. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Brooks Laboratories Limited reported revenue of ₹857M in FY2026 versus ₹912M in FY2022, a compound −1.5%/yr. Reported net income was ₹246M in FY2026.
BROOKS screens 43% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Brooks Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Brooks Laboratories Limited (BROOKS) overvalued or undervalued?
What is the fair value of BROOKS?
What is the quality score of BROOKS?
What is the revenue of Brooks Laboratories Limited (BROOKS)?
What is the net profit margin of BROOKS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Brooks Laboratories Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.